Search - tctmd.com

Displaying 41 - 60 of 943

Sort: Relevancy | Date

News Daily News

GLP-1s Reduce Limb and Cardiac Events in Peripheral Artery Disease

L.A. McKeown

June 12, 2025

News Daily News

JACC Dedicates Issue to Deep Dive on Latest ACS Guidelines

Todd Neale

June 06, 2025

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

News Conference News ESOC 2025

Less Intense Checks May Be OK After IV Thrombolysis for Stroke: OPTIMISTmain

Todd Neale

May 28, 2025

News Conference News EuroPCR 2025

Meta-analysis Quashes Hopes for Routine Embolic Protection in TAVI

Michael O'Riordan

May 21, 2025

News Conference News EuroPCR 2025

Complete Revascularization in STEMI Still Superior at 10 Years: DANAMI-3-PRIMULTI

Michael O'Riordan

May 20, 2025

News Daily News

Apixaban Bests Rivaroxaban, Warfarin in Preventing VTE Recurrence and Bleeding

L.A. McKeown

May 16, 2025

News Conference News European Congress on Obesity 2025

App-Based Support Aids Weight Loss With Semaglutide, Studies Show

Michael O'Riordan

May 13, 2025

News Conference News European Congress on Obesity 2025

Tirzepatide Tops Semaglutide for Weight Loss: SURMOUNT-5

Michael O'Riordan

May 12, 2025

News Conference News EAS 2025

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

Yael L. Maxwell

May 08, 2025

News Daily News

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Michael O'Riordan

May 07, 2025

News Daily News

Lorundrostat Lowers BP in Treatment-Resistant Hypertension: Advance-HTN

Yael L. Maxwell

April 29, 2025

News Daily News

Medicaid Patients With Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds

Michael O'Riordan

April 25, 2025

News Daily News

Knowledge of Genetic Risk for CAD Bolsters Prevention, Reduces MACE

Caitlin E. Cox

April 23, 2025

News Daily News

Oral GLP-1 Drug Shines in Phase III ACHIEVE-1 Trial, Lilly Says

Caitlin E. Cox

April 17, 2025

News Conference News ACC 2025

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

L.A. McKeown

April 10, 2025

News Conference News ACC 2025

FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints

L.A. McKeown

April 03, 2025

News Conference News ACC 2025

Strike Two: BHF PROTECT-TAVI Throws Cold Water on Embolic Protection

Michael O'Riordan

March 30, 2025

News Daily News

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

Michael O'Riordan

March 26, 2025

Advertisement

GLP-1s Reduce Limb and Cardiac Events in Peripheral Artery Disease

JACC Dedicates Issue to Deep Dive on Latest ACS Guidelines

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Less Intense Checks May Be OK After IV Thrombolysis for Stroke: OPTIMISTmain

Meta-analysis Quashes Hopes for Routine Embolic Protection in TAVI

Complete Revascularization in STEMI Still Superior at 10 Years: DANAMI-3-PRIMULTI

Apixaban Bests Rivaroxaban, Warfarin in Preventing VTE Recurrence and Bleeding

App-Based Support Aids Weight Loss With Semaglutide, Studies Show

Tirzepatide Tops Semaglutide for Weight Loss: SURMOUNT-5

Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM

Inclisiran Effective as Monotherapy for Lower-Risk Primary Prevention

Lorundrostat Lowers BP in Treatment-Resistant Hypertension: Advance-HTN

Medicaid Patients With Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds

Knowledge of Genetic Risk for CAD Bolsters Prevention, Reduces MACE

Oral GLP-1 Drug Shines in Phase III ACHIEVE-1 Trial, Lilly Says

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

FAIR-HF2: Another IV Iron Trial Fails to Impact Hard Endpoints

Strike Two: BHF PROTECT-TAVI Throws Cold Water on Embolic Protection

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content